BioMarin Says It's Got The Hemophilia Therapy Data For Approval And Value
Executive Summary
The company will begin discussions with regulators in the US and Europe for a gene therapy for hemophilia A based on the results of new data, with a launch targeted for late 2020. Durability remains a question.
You may also be interested in...
EU Fast-Track Success For BioMarin’s Valrox But Not For Amarin’s Vascepa
Just one of four accelerated assessment requests that were decided on at the European Medicines Agency this month is known to have been granted – for BioMarin’s Valrox. There was rejection for Amarin; Roche and Orchard are keeping the outcomes to themselves.
ICER 2020 Priorities Include Drugs For Ulcerative Colitis, NASH And Gene Therapies
The Institute for Clinical and Economic Review has a full agenda planned for 2020, starting with potential new oral drugs for migraine.
Spotlight on Q1 Pharma M&A Merry-Go-Round
Q1 2019 saw a jump in merger and acquisition activity. Informa’s Biomedtracker has cast an analytical eye on three of the major deals, namely buys by Roche, Lilly and BMS.